Related Experiment Videos
[Subclinical functional disorders of the thyroid gland]
1Academisch Medisch Centrum/Universiteit van Amsterdam, afd. Endocrinologie en Stofwisselingsziekten, Amsterdam. e.p.m.corssmit@lumc.nl
Nederlands Tijdschrift Voor Geneeskunde
|July 9, 2003
Summary
Subclinical thyroid dysfunction requires individualized treatment decisions due to limited evidence. Treatment for subclinical hypothyroidism may be considered in specific cases, while subclinical hyperthyroidism warrants treatment for atrial fibrillation or nodular goiter.
Area of Science:
- Endocrinology
- Thyroid Disorders
- Internal Medicine
Context:
- Subclinical hypothyroidism (SCH) presents with non-specific symptoms like fatigue, cognitive issues, and lipid disturbances.
- Subclinical hyperthyroidism (SH) is linked to atrial fibrillation, osteoporosis, and dementia.
- Current evidence from prospective randomized trials with hard outcomes is insufficient for general treatment recommendations.
Purpose:
- To outline evidence-based considerations for treating subclinical thyroid dysfunction.
- To guide individualized treatment decisions for patients with SCH and SH.
- To highlight specific patient groups who may benefit from intervention.
Summary:
- Treatment for SCH may be considered with positive thyroid peroxidase antibodies, TSH > 10 mU/l, cardiovascular risk factors, infertility, or pregnancy.
- A 3-month trial treatment for SCH is an option for fatigue, depression, or cognitive dysfunction, with symptom improvement in ~25% of cases.
- Treatment for SH is advised for nodular goiter and atrial fibrillation; otherwise, an expectant approach with monitoring is recommended.
Impact:
- Promotes individualized patient care for subclinical thyroid disorders.
- Reduces the risk of adverse outcomes associated with untreated SCH and SH.
- Informs clinical practice regarding the judicious use of thyroid hormone replacement and monitoring strategies.